IL2 and melanoma: Studies in a B16 melanoma model have shown that immunotherapy with an IL-2/anti-IL-2 mAb complex only binding to the IL-2βγ receptor abrogated IL-2 therapy mediated side effects (pulmonary edema) and led to a vigorous activation of cytotoxic immune cells with strong antitumor reactivity [5].